Lipopolysaccharides (LPS) are large molecules anchored in the outer membrane of gram-negative bacteria, where they serve as both a structural shield for the microbe and a powerful trigger for the human immune system. Sometimes called endotoxins, they are among the most potent activators of inflammation known to medicine. Their importance stretches from acute emergencies like septic shock to slower-burning problems like metabolic disease, and they even play a surprising role in vaccine design and pharmaceutical safety testing.
The Three-Part Architecture
Every LPS molecule shares a basic blueprint made of three regions stacked together. The innermost part, lipid A, is embedded directly in the bacterial outer membrane. It anchors the whole molecule and is the portion your immune system reacts to most violently. Above lipid A sits a short chain of sugars called the core oligosaccharide, and extending outward from the cell surface is the O-antigen, a long, repeating sugar chain that varies enormously from one bacterial species to another.
Lipid A is the most conserved piece. Its fatty acid chains help create a tight permeability barrier that protects the bacterium from antibiotics and detergents trying to get in. That barrier is not just a passive wall; LPS is essential to the rigidity and integrity of the outer membrane in nearly all gram-negative bacteria tested so far.
The O-antigen is a different story. Its sugar sequences are so diverse that researchers use them to classify bacterial strains. This diversity helps bacteria evade immune responses, resist complement killing, and adapt to different environments. A single species can produce O-antigens with completely different sugar building blocks depending on the strain. For example, structural analysis of the bacterium Delftia acidovorans revealed an O-antigen built from a novel sugar sequence not seen elsewhere, illustrating just how creative bacteria can be with this part of the molecule.
How Your Immune System Spots LPS
Your body has evolved an elaborate detection system specifically for LPS, and it works in two separate locations: outside and inside your cells.
The extracellular system revolves around a receptor called TLR4. When gram-negative bacteria die or break apart, LPS fragments float free. A blood protein called LBP loosens individual LPS molecules from bacterial debris, then hands them off to a protein called CD14, which in turn delivers them to a complex of MD-2 and TLR4 sitting on the surface of immune cells like macrophages and dendritic cells. The fatty acid chains of lipid A physically cross-link two TLR4-MD2 pairs together, triggering a signal cascade inside the cell.
TLR4 is unusual among immune receptors because it activates two distinct signaling branches. One, called the MyD88 pathway, drives rapid production of inflammatory molecules. The other, the TRIF pathway, triggers a different set of responses including the production of interferons. Both branches working together produce the strongest immune activation.
But TLR4 is not the only LPS sensor. If LPS gets inside a cell’s cytoplasm, a completely separate alarm system kicks in. In humans, enzymes called caspase-4 and caspase-5 bind directly to intracellular LPS. When activated, these enzymes trigger pyroptosis, a form of explosive cell death where the cell essentially ruptures and spills its contents, alerting neighboring cells to danger. The pore-forming protein GSDMD executes this cell death after being activated by the caspases.
When the Alarm Becomes the Problem
In small doses, the immune response to LPS is protective. It mobilizes white blood cells, ramps up inflammation at the site of infection, and helps kill invading bacteria. The problem arises when large amounts of LPS flood the bloodstream all at once, as can happen during a severe gram-negative infection.
A massive LPS load triggers an exaggerated immune response that damages the body’s own tissues. This is the engine behind septic shock. Blood vessels dilate uncontrollably, blood pressure drops, clotting goes haywire, and organs begin to fail. The pattern of organ damage in what clinicians call endotoxic septic shock typically includes liver dysfunction, acute kidney injury, and various forms of blood vessel damage ranging from abnormal clotting to destruction of small blood vessels.
Roughly five to seven million patients worldwide develop sepsis with very high endotoxin activity each year, and more than half of them die. What makes endotoxin especially treacherous is that it does not have to come from an active bacterial infection. In any form of severe illness that damages the gut lining, including conditions as varied as major surgery and COVID-19, bacteria or bacterial products from the intestine can leak into the bloodstream. This “translocation” of LPS means endotoxin can play a role even in septic shock that was not originally caused by a gram-negative infection.
The Slow Burn of Metabolic Endotoxemia
Sepsis is an acute crisis, but LPS also appears to cause harm at much lower levels over longer periods. Metabolic endotoxemia is a condition in which blood LPS levels are chronically elevated without any obvious infection. The rise is modest compared with sepsis, but the consequences accumulate.
Research has linked this low-grade endotoxin exposure to obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and even neurodegenerative conditions. A Mendelian randomization study found that genetically predicted increases in LPS were associated with higher odds of developing both NAFLD and obesity, along with unfavorable changes in blood lipids. A separate systematic review and meta-analysis confirmed that patients with NAFLD have elevated blood endotoxin levels compared with liver-healthy controls, and that this elevation persists even after accounting for differences in body weight.
The metabolic endotoxemia hypothesis proposes that gut-derived LPS acts in a hormone-like manner, influencing metabolism by sustaining low-level immune activation in fat tissue, the liver, and elsewhere. Research in this area has accelerated over the past decade, with the gut microbiome now recognized as the primary source of the endotoxin that reaches the bloodstream in these chronic conditions.
How LPS Hitches a Ride During Fat Absorption
One of the more unexpected discoveries about LPS is how it crosses the intestinal barrier. Your gut is home to enormous numbers of gram-negative bacteria, all shedding LPS. Normally, the intestinal lining keeps most of it out. But when you eat a meal containing fat, the absorption machinery that carries dietary fat into your blood can also carry LPS along with it.
Intestinal cells package dietary fats into particles called chylomicrons for transport into the bloodstream. Experiments have shown that long-chain fatty acids, the kind abundant in most dietary fats, promote LPS absorption, while short-chain fatty acids do not. When chylomicron formation was blocked experimentally, LPS transport dropped sharply. Most of the LPS that made it into the blood was found riding on chylomicron remnants.
More detailed work has revealed that LPS crosses the intestinal lining during fat absorption through specific cellular mechanisms rather than leaking between cells. This transport can be inhibited, and the gut hormone GLP-2 (which some diabetes drugs mimic) appears to reduce it. This finding is part of why high-fat meals can temporarily raise blood endotoxin levels in healthy people, and why habitual high-fat diets may contribute to the sustained low-grade endotoxemia seen in metabolic disease.
How Your Body Neutralizes LPS
Given how dangerous LPS can be, it would be a problem if the body had no way to shut it down. The key detoxification enzyme is called acyloxyacyl hydrolase (AOAH). This lipase, found mainly in the liver and spleen, clips off the secondary fatty acid chains that lipid A needs in order to activate TLR4. Without those chains, LPS can no longer trigger the receptor, and its ability to cause tissue damage drops by a factor of 100 or more.
AOAH was originally discovered in human white blood cells called neutrophils, which encounter LPS at infection sites. The enzyme’s selectivity is remarkable: it removes only the specific acyl chains required for immune signaling, leaving the rest of the molecule intact. This targeted deacylation effectively converts a potent immune activator into a largely inert molecule.
Endotoxin Tolerance
Your immune system can also learn to dial down its reaction to LPS through a phenomenon called endotoxin tolerance. The concept was first described when researchers noticed that animals exposed to a small, non-lethal dose of endotoxin subsequently survived a dose that would otherwise have killed them. The animals’ immune cells, particularly monocytes and macrophages, had entered a refractory state where they produced far less inflammation in response to a second LPS exposure.
Endotoxin tolerance is not the same as adaptive immunity (where you build antibodies against a specific pathogen). It is a reprogramming of the innate immune response itself. While it can be protective during infection by preventing a runaway inflammatory spiral, it has a downside: tolerized immune cells may be less effective at fighting new infections. In intensive care patients who survive an initial bout of sepsis, this immunosuppressed state may explain why secondary infections are so common and so dangerous. Several mechanisms contribute to endotoxin tolerance, and researchers are still working out the full picture.
Testing for Endotoxin and the Horseshoe Crab Connection
LPS is extremely heat-stable. Standard sterilization methods that kill bacteria can actually release more endotoxin in the process, since the molecules survive temperatures that destroy living cells. This means every injectable drug, every implantable medical device, and every vial of intravenous fluid must be tested for endotoxin contamination before it reaches a patient. Regulatory agencies worldwide mandate these tests.
For decades, the primary testing method has been the Limulus Amebocyte Lysate (LAL) test, which uses blood cells harvested from Atlantic horseshoe crabs. Horseshoe crab blood contains a clotting factor that reacts dramatically to even trace amounts of LPS, gelling on contact. The pharmaceutical industry bleeds hundreds of thousands of horseshoe crabs each year for this purpose, a practice that has raised serious conservation and ethical concerns.
A synthetic alternative called recombinant Factor C (rFC) has been developed that eliminates the need for animal products entirely. Long-term proficiency testing over six years has shown that rFC-based assays are comparable to LAL and in some cases produce better endotoxin recovery rates. Both major rFC-based systems met all acceptance criteria defined by standard bacterial endotoxin testing protocols. Regulatory acceptance of rFC has been growing, though LAL remains dominant in North America and Europe for now.
Turning a Toxin Into a Vaccine Ingredient
Perhaps the most counterintuitive use of LPS is in vaccines. The same molecule that can cause septic shock at high doses turns out to be an excellent immune booster at very low doses, if modified correctly. Monophosphoryl lipid A (MPLA) is a chemically detoxified derivative of lipid A that retains the ability to activate TLR4 and stimulate adaptive immune responses while shedding the dangerous inflammatory side effects of full LPS.
MPLA was among the first of a new generation of TLR-based vaccine adjuvants used on a mass scale in humans. It works by pushing the immune system toward a stronger, longer-lasting response to whatever antigen is in the vaccine. When formulated with antigens like hepatitis B surface antigen, tetanus toxoid, or influenza proteins and delivered intranasally, MPLA enhanced both systemic antibody responses and mucosal IgA production, the type of antibody that protects surfaces like the nose and gut.
Researchers continue to refine the concept. Newer designs conjugate MPLA with other immune-stimulating sugar molecules like rhamnose, creating hybrid adjuvants that activate multiple immune pathways simultaneously. In mouse studies, these conjugates showed synergistic effects, boosting antibody production against both protein and carbohydrate antigens beyond what either component achieved alone.
Antibiotic Resistance Through Lipid A Remodeling
Polymyxins, including colistin, are considered last-resort antibiotics for multidrug-resistant gram-negative infections. They work by binding to the negatively charged lipid A portion of LPS, disrupting the outer membrane and killing the bacterium. But bacteria have found ways to fight back by remodeling lipid A itself.
The most common resistance mechanisms involve adding positively charged chemical groups to lipid A. Specifically, bacteria attach 4-amino-L-arabinose or phosphoethanolamine to the phosphate groups on lipid A, reducing its net negative charge. With less negative charge, lipid A no longer attracts the positively charged polymyxin molecules as strongly, and the antibiotic loses its grip on the membrane.
What has alarmed public health authorities is that this resistance can spread between bacteria on mobile genetic elements. The gene mcr-1, carried on plasmids, encodes an enzyme that adds phosphoethanolamine to lipid A. Because plasmids transfer easily between bacterial species, mcr-1 has been found in multiple types of gram-negative pathogens worldwide. When Klebsiella pneumoniae acquires mcr-1-mediated lipid A modifications, colistin can no longer effectively kill it. Interestingly, one mouse study found that these lipid A changes did not alter the innate immune response to the bacteria during pneumonia, meaning the resistance modification helps bacteria survive antibiotics without necessarily changing how the immune system sees them.
Not All LPS Is Created Equal
The textbook description of LPS comes from well-studied pathogens like E. coli and Salmonella, but the molecule takes dramatically different forms across the bacterial world. Cyanobacteria, the photosynthetic microbes found in freshwater and marine environments, produce LPS with a structure so different that it challenges assumptions about how the molecule works.
Cyanobacterial LPS lacks two sugar molecules, heptose and KDO, that are considered hallmarks of the core region in conventional gram-negative LPS. Their lipid A also lacks phosphate groups and contains unusual odd-chain fatty acids not found in enteric bacteria. These structural differences have functional consequences: cyanobacterial lipid A can range from being a weak TLR4 activator to actually acting as an LPS antagonist, blocking the receptor rather than triggering it.
This diversity matters for public health because cyanobacterial blooms in lakes and reservoirs expose millions of people to these unconventional LPS forms through drinking water and recreation. The biological effects of cyanobacterial LPS are still being sorted out, but the structural differences make it clear that treating all LPS as interchangeable oversimplifies the picture. Lipid A structures across the bacterial kingdom express properties ranging from strong immune activation through weak activity to outright antagonism, depending on the specific arrangement of fatty acids and charged groups.
Why LPS Keeps Showing Up in New Research
LPS sits at an intersection of microbiology, immunology, metabolism, pharmacology, and environmental health. Its dual identity as a structural necessity for bacteria and a potent immune activator creates a tension that shapes everything from how antibiotics work to why a high-fat diet might inflame your liver. The molecule’s involvement in conditions as different as septic shock and fatty liver disease means that researchers in fields that rarely overlap find themselves studying the same molecule from opposite angles. Clinicians trying to neutralize LPS during sepsis, vaccinologists harnessing its immune-boosting power, conservation biologists worried about horseshoe crab populations, and microbiologists cataloging its structural diversity in cyanobacteria are all, in a sense, working on different facets of the same problem. That breadth of relevance is unusual for a single class of molecules, and it is why lipopolysaccharides keep generating new questions long after their basic biology was worked out.